CannLabs, Inc. (CANL) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.09 means the share price is 0.09 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCannLabs, Inc. (CANL) trades at $0.0001. CannLabs, Inc. operates as a specialized cannabis testing laboratory in the United States, offering a comprehensive suite of analytical services to ensure product quality and safety. Sector: Industrials.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for CANL: CANL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CannLabs, Inc. (CANL) Industrial Operations Profile
CannLabs, Inc. is a U.S.-based cannabis testing laboratory providing essential analytical services, including potency, residual solvent, and microbiological testing, alongside data analytics and education. The company supports quality assurance and regulatory compliance within the rapidly evolving cannabis sector, headquartered in Denver, Colorado.
What Is the Investment Thesis for CANL?
CannLabs, Inc. operates within the critical and expanding cannabis testing sector, providing essential quality assurance and regulatory compliance services across the United States. The company's comprehensive testing portfolio, encompassing potency, residual solvent, microbiological, and heavy metals analysis, positions it as a key infrastructure provider for cultivators and processors. With a reported profit margin of 19.8% and a gross margin of 47.0%, CannLabs demonstrates operational efficiency in its specialized service offerings. The ongoing expansion of cannabis legalization across more U.S. states presents a significant growth catalyst, driving increased demand for mandatory product testing. The company's additional services, including data/analytics and consulting, offer diversified revenue streams and strengthen client relationships by providing value beyond basic testing. The 'OTC Other' classification and 'Unknown' disclosure status introduce significant transparency and liquidity risks that warrant thorough due diligence.
Based on FMP financials and quantitative analysis
CANL Key Highlights
The company maintains a strong gross margin of 47.0%, indicating efficient management of its service delivery costs.
- CannLabs, Inc. reported a profit margin of 19.8%, reflecting its ability to convert revenue into net income within its specialized market.
- With a P/E ratio of 0.09, the company's valuation metrics suggest a potentially low earnings multiple relative to its profitability.
- The company exhibits a high Beta of 5.59, indicating significantly higher volatility compared to the broader market.
- CannLabs, Inc. operates with a market capitalization of $0.00B, suggesting a micro-cap or thinly traded status.
Who Are CANL's Competitors?
CANL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| LICN Lichen International Limited | $1.00 | -2.90% | — | |
| CRE Cre8 Enterprise Limited Class A Ordinary Shares | $2.70 | -0.37% | $5.44M | 63 5-pillar |
| THH TryHard Holdings Limited | $1.50 | -5.06% | $7.51M | — |
| MSGY Masonglory Limited | $4.39 | -14.99% | $7.81M | 33 5-pillar |
| SST System1, Inc. | $2.44 | -7.58% | $24.4M | — |
| ANPA Rich Sparkle Holdings Limited | $1.97 | -4.37% | $29.8M | — |
| NTIP Network-1 Technologies, Inc. | $1.63 | +1.88% | $37.3M | 55 5-pillar |
| OMEX Odyssey Marine Exploration, Inc. | $0.66 | -3.75% | $38.9M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CANL's Key Strengths?
Comprehensive range of specialized cannabis testing laboratory services.
- Strong gross margin of 47.0% and profit margin of 19.8% indicate operational efficiency.
- Headquartered in Denver, Colorado, a mature cannabis market, potentially providing a strategic base.
- Offers value-added services like data/analytics, consulting, and education beyond core testing.
What Are CANL's Weaknesses?
Market capitalization of $0.00B suggests very limited market presence or liquidity.
- Trades on the 'OTC Other' tier with 'Unknown' disclosure status, indicating significant transparency challenges.
- High Beta of 5.59 points to extreme stock price volatility.
- Reliance on the evolving and fragmented regulatory landscape of the cannabis industry.
What Are the Key Risks for CANL?
The 'Unknown' disclosure status poses a significant risk to investors due to a complete lack of transparent financial and operational information.
- Trading on the 'OTC Other' tier with a $0.00B market cap implies extremely low liquidity, making it difficult to buy or sell shares efficiently and potentially leading to significant price volatility.
- Rapid and unpredictable changes in cannabis regulations across different U.S. states could necessitate costly adaptations to testing protocols and compliance frameworks.
- Intense competition within the cannabis testing market could pressure pricing and market share, impacting profitability and growth prospects.
- The high Beta of 5.59 indicates extreme sensitivity to market fluctuations, suggesting that the stock price could experience substantial declines during broader market downturns.
What Threats Does CANL Face?
- Intense competition from other specialized cannabis testing labs and larger analytical service providers.
- Rapid changes in cannabis regulations across states, requiring continuous adaptation and investment.
- Technological advancements in testing equipment or methodologies that could render current processes obsolete.
- Potential for consolidation in the cannabis industry, leading to fewer, larger clients with greater bargaining power.
What Are CANL's Competitive Advantages?
- Comprehensive suite of testing services covering a broad spectrum of analytical needs, from basic potency to advanced genetic analysis.
- Specialized expertise in navigating complex and evolving state-specific cannabis regulations.
- Established laboratory infrastructure and technical capabilities in a highly specialized field.
- Potential for proprietary methodologies or data insights from extensive testing operations.
- Reputation as a trusted third-party validator, crucial for building consumer confidence in a regulated industry.
What Does CANL Do?
CannLabs, Inc. is a dedicated provider of cannabis testing laboratory services across the United States, headquartered in Denver, Colorado. The company plays a critical role in the burgeoning cannabis industry by ensuring product safety, quality, and compliance with various state-level regulations. Its comprehensive suite of testing services addresses a wide spectrum of analytical needs for cannabis cultivators, processors, and dispensaries. Key testing offerings include potency testing, which quantifies cannabinoid content such as THC and CBD; residual solvent analysis, vital for ensuring products are free from harmful processing chemicals; and microbiological testing to detect contaminants like mold, yeast, and bacteria. Additionally, CannLabs, Inc. performs pesticide testing, heavy metals testing, and nutrient analysis, all crucial for consumer safety and product integrity. The company also delves into more specialized areas such as terpenes analysis, which identifies compounds responsible for aroma and flavor profiles, and shelf-life/stability studies to determine product longevity. Furthermore, CannLabs, Inc. offers advanced genetic services, including gene expression testing and genotyping/phenotyping testing, providing deeper insights into cannabis strains. Beyond its core laboratory services, CannLabs, Inc. extends its value proposition through data and analytics offerings, providing crucial market insights and trend analysis to its clients. The company also engages in consulting services, leveraging its expertise to guide businesses through regulatory complexities and operational best practices. Complementing these services, CannLabs, Inc. provides education services, aiming to elevate industry standards and knowledge among stakeholders. With 37 employees, CannLabs, Inc. positions itself as a foundational support system for the cannabis industry, contributing to its professionalization and consumer trust.
What Products and Services Does CANL Offer?
- Provides potency testing to quantify cannabinoid content (e.g., THC, CBD) in cannabis products.
- Conducts residual solvent analysis to ensure products are free from harmful processing chemicals.
- Performs microbiological testing to detect contaminants like mold, yeast, and bacteria.
- Offers pesticide testing and heavy metals testing for consumer safety and regulatory compliance.
- Provides nutrient analysis and terpenes analysis to understand product composition and characteristics.
- Undertakes shelf-life and stability studies to determine product longevity and quality over time.
- Engages in gene expression testing and genotyping/phenotyping for advanced strain analysis.
- Offers data/analytics, consulting, and education services to support the cannabis industry.
How Does CANL Make Money?
- Generates revenue primarily through fees for a wide range of analytical cannabis testing services.
- Monetizes its expertise by offering data and analytics services to clients for market insights.
- Provides consulting services, advising cannabis businesses on regulatory compliance and operational best practices.
- Offers education services, potentially through workshops or training programs, to industry professionals.
What Industry Does CANL Operate In?
CannLabs, Inc. is positioned within the Drug Manufacturers - Specialty & Generic industry, specifically focusing on the analytical testing segment of the rapidly expanding cannabis market. This niche sector is characterized by stringent and evolving regulatory requirements across various U.S. states where cannabis is legal. The demand for cannabis testing services is directly tied to the growth of both medical and recreational cannabis markets, driven by increasing consumer awareness of product safety and quality. The competitive landscape includes other specialized cannabis testing laboratories, as well as broader analytical service providers that may have expanded into cannabis. Key market trends include the standardization of testing protocols, advancements in analytical technologies, and the increasing need for robust data to inform product development and regulatory compliance. CannLabs' comprehensive service offering, from potency to genetic testing, positions it to address diverse client needs within this dynamic and highly regulated environment.
Who Are CANL's Key Customers?
- Cannabis cultivators and growers requiring testing for harvest quality and compliance.
- Cannabis processors and manufacturers needing analysis for extracts, edibles, and other derivative products.
- Dispensaries and retailers seeking third-party verification of product quality and safety.
- Researchers and product developers requiring specialized genetic and stability studies.
- New market entrants and established businesses seeking consulting and educational support.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
CannLabs, Inc. operates in the Industrials sector. It is headquartered in Denver, US. The company is led by CEO Mark C. Mirken. CANL has traded publicly since 2012.
Key Financial Metrics
Return on equity for CannLabs, Inc. stands at 37.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 26.8%, showing how much profit it generates from its asset base. CANL trades at a trailing price-to-earnings ratio of 0.09, below the Healthcare sector average of ~21.10x. A current ratio of 23.93 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
CannLabs, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.26 places it in the safe zone, indicating low near-term bankruptcy risk.
CANL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CANL Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Nov 12, 2019
-
Stocks That Hit 52-Week Lows On Friday
· Oct 4, 2019
CANL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CANL.
Price Targets
Wall Street price target analysis for CANL.
CANL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CANL; grades run from A+ (80-100) to F (below 30).
CANL OTC Market Information
The 'OTC Other' tier, where CannLabs, Inc. trades, represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing requirements regarding financial standards, corporate governance, and disclosure, companies on 'OTC Other' have minimal or no reporting obligations to the SEC. This tier is typically for companies that are distressed, defunct, or have not provided current information to OTC Markets Group. It contrasts sharply with OTCQX and OTCQB, which have higher financial and disclosure standards, aiming for greater transparency and investor confidence. Investing in 'OTC Other' stocks carries significantly elevated risks due to the lack of readily available information and regulatory oversight.
- OTC Tier: OTC Other
- **Lack of Transparency:** The 'Unknown' disclosure status means investors have no access to current financial statements, operational reports, or material news, making informed decision-making nearly impossible.
- **Extremely Low Liquidity:** Trading on the 'OTC Other' tier with a $0.00B market cap implies very few buyers and sellers, leading to wide bid-ask spreads and significant difficulty in trading shares.
- **High Volatility:** A Beta of 5.59 indicates extreme price swings, which, combined with low liquidity, can result in rapid and substantial capital losses.
- **Limited Regulatory Oversight:** Companies on 'OTC Other' are subject to minimal regulatory scrutiny compared to exchange-listed or even higher-tier OTC stocks, increasing the risk of fraud or mismanagement.
- **Difficulty in Valuation:** Without reliable financial data and market activity, accurately valuing the company's shares is exceptionally challenging, leading to speculative pricing.
- Verify any available information directly from the company or independent third-party sources, if possible, given the 'Unknown' disclosure status.
- Assess the current operational status and market presence of CannLabs, Inc. beyond the provided business description.
- Investigate any historical financial filings or public records that might exist, even if not current.
- Understand the specific regulatory environment in which the company operates and its compliance track record.
- Evaluate the competitive landscape and CannLabs' actual market share or differentiation, if any data can be found.
- Research the background and track record of Mark C. Mirken and other key management personnel, if information is available.
- Consider the potential for delisting or further market tier degradation given the current status.
- The company is based in Denver, Colorado, a significant hub for the cannabis industry, which could indicate a strategic location.
- It operates in a legitimate and growing sector (cannabis testing), providing essential services for product quality and safety.
- The company has a stated number of employees (37), suggesting an active operational presence.
- The comprehensive list of testing services indicates a specialized and technical business model.
CANL Industrials Stock FAQ
What are the main risks for CANL?
The primary risks for CannLabs, Inc. are multifaceted, stemming significantly from its market classification and the nature of the cannabis industry.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information on CEO background, track record, and tenure is not available in the provided source data and has been marked as 'Unknown' or 'null'.
- The 'Unknown' disclosure status for OTC analysis significantly limits the depth of financial and operational assessment.